Sec Form 4 Filing - Gridley Adam @ HISTOGENICS CORP - 2018-10-01

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Gridley Adam
2. Issuer Name and Ticker or Trading Symbol
HISTOGENICS CORP [ HSGX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
President and CEO
(Last) (First) (Middle)
C/O HISTOGENICS CORPORATION, 830 WINTER STREET, 3RD FLOOR
3. Date of Earliest Transaction (MM/DD/YY)
10/01/2018
(Street)
WALTHAM, MA02451
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 7.99 10/01/2018 D( 1 ) 197,435 ( 2 ) 04/29/2024 Common Stock 197,435 $ 0 0 D
Employee Stock Option (Right to Buy) $ 0.568 10/01/2018 A( 1 ) 197,435 ( 2 ) 04/29/2024 Common Stock 197,435 $ 0 197,435 D
Employee Stock Option (Right to Buy) $ 8.97 10/01/2018 D( 1 ) 38,220 ( 3 ) 07/16/2024 Common Stock 38,220 $ 0 0 D
Employee Stock Option (Right to Buy) $ 0.568 10/01/2018 A( 1 ) 38,220 ( 3 ) 07/16/2024 Common Stock 38,220 $ 0 38,220 D
Employee Stock Option (Right to Buy) $ 9.96 10/01/2018 D( 1 ) 104,000 ( 4 ) 02/26/2025 Common Stock 104,000 $ 0 0 D
Employee Stock Option (Right to Buy) $ 0.568 10/01/2018 A( 1 ) 104,000 ( 4 ) 02/26/2025 Common Stock 104,000 $ 0 104,000 D
Employee Stock Option (Right to Buy) $ 1.58 10/01/2018 D( 1 ) 175,000 ( 5 ) 12/16/2026 Common Stock 175,000 $ 0 0 D
Employee Stock Option (Right to Buy) $ 0.568 10/01/2018 A( 1 ) 175,000 ( 5 ) 12/16/2026 Common Stock 175,000 $ 0 175,000 D
Employee Stock Option (Right to Buy) $ 1.72 10/01/2018 D( 1 ) 175,000 ( 6 ) 02/14/2027 Common Stock 175,000 $ 0 0 D
Employee Stock Option (Right to Buy) $ 0.568 10/01/2018 A( 1 ) 175,000 ( 6 ) 02/14/2027 Common Stock 175,000 $ 0 175,000 D
Employee Stock Option (Right to Buy) $ 2.63 10/01/2018 D( 1 ) 300,000 ( 7 ) 02/15/2028 Common Stock 300,000 $ 0 0 D
Employee Stock Option (Right to Buy) $ 0.568 10/01/2018 A( 1 ) 300,000 ( 7 ) 02/15/2028 Common Stock 300,000 $ 0 300,000 D
Employee Stock Option (Right to Buy) $ 9.96 10/01/2018 D( 8 ) 60,000 ( 9 ) 02/26/2025 Common Stock 60,000 $ 0 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gridley Adam
C/O HISTOGENICS CORPORATION
830 WINTER STREET, 3RD FLOOR
WALTHAM, MA02451
X President and CEO
Signatures
/s/ Adam Gridley 10/02/2018
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" (any stock option awarded by the Issuer under it 2012 Equity Incentive Plan or 2013 Equity Incentive Plan with an exercise price greater than $ 0.75628 per share held by current service providers other than the non-employee members of the Issuer's board of directors) has been amended to reduce such exercise price to $0.568, which was the closing price of a share of the Issuer's common stock reported on The Nasdaq Capital Market on October 1, 2018. There have been no other changes to the terms of the Relevant Options.
( 2 )The stock option was originally granted to the Reporting Person on April 30, 2014 and is vested with respect to all of the shares underlying the option.
( 3 )The stock option was originally granted to the Reporting Person on July 17, 2014 and is vested with respect to all of the shares underlying the option.
( 4 )The stock option was originally granted to the Reporting Person on February 26, 2015. This option vests over four (4) years of service following February 26, 2016, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and in thirty-six (36) equal monthly installments thereafter.
( 5 )The stock option was originally granted to the Reporting Person on December 16, 2016. This option vests over four (4) years of service to the Issuer following February 26, 2016, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service to the Issuer following such date and the balance vesting in thirty-six (36) equal monthly installments thereafter.
( 6 )The stock option was originally granted to the Reporting Person on February 14, 2017, This option vests over four (4) years of service to the Issuer following February 14, 2017, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service to the Issuer following such date and the balance vesting in thirty-six (36) equal monthly installments thereafter.
( 7 )The stock option was originally granted to the Reporting Person on February 16, 2018. This option vests over four (4) years of service to the Issuer following February 16, 2018, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service to the Issuer following such date and the balance vesting in thirty-six (36) equal monthly installments thereafter.
( 8 )This transaction reflects the cancellation for no consideration of certain outstanding stock options to purchase common stock of the Issuer that were previously granted to the Reporting Person (the "Cancelled Options").
( 9 )The Cancelled Option was originally granted to the Reporting Person on February 26, 2015 and was to vest in full if the Issuer's Common Stock price reached $19.92 per shares or above for any consecutive sixty (60) day period within four (4) years of the date of grant.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.